83 results
Page 2 of 5
8-K
EX-99.1
9hhmgepy
12 Aug 22
Axcella Reports Second Quarter Financial Results and Provides Business Update
8:11am
8-K
ydgr2lth
2 Aug 22
Axcella Announces Highly Promising Results from Phase 2a Placebo Controlled Clinical Trial for Long COVID
4:06pm
8-K
EX-99.2
bkc8jtvhwhuvpg7
2 Aug 22
Axcella Announces Highly Promising Results from Phase 2a Placebo Controlled Clinical Trial for Long COVID
4:06pm
8-K
EX-99.1
ve9 20rdqjy6pnv7mxyz
2 Aug 22
Axcella Announces Highly Promising Results from Phase 2a Placebo Controlled Clinical Trial for Long COVID
4:06pm
8-K
EX-99.1
n67nylqr95de rm
26 May 22
Axcella Announces Completion of Enrollment of Clinical Trial for Long COVID and Has Prioritized its Clinical Portfolio
8:12am
8-K
EX-99.1
l27q20w2
5 May 22
Axcella Reports First Quarter Financial Results and Provides Business Update
7:41am
8-K
EX-99.1
fn1m605dzwolu
30 Mar 22
Axcella Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
8:05am
8-K
EX-10.1
3b9ckdxrtrf3 dus8j
16 Mar 22
Axcella Therapeutics Announces $25 Million Registered Direct Offering of Common Stock Priced At the Market
8:30am
424B5
we6wxi
16 Mar 22
Prospectus supplement for primary offering
8:00am
8-K
EX-99.1
1xy39p4e t910ple
7 Feb 22
Axcella Therapeutics Announces Appointment of New Chief Financial Officer
4:00pm
8-K
EX-99.1
o4lps 3xzwu
10 Jan 22
Other Events
8:00am
8-K
EX-99.1
8f8je4uo57qlomtj5
7 Dec 21
Departure of Directors or Certain Officers
6:15am
8-K
EX-99.1
fpxhy oc6fxob
10 Nov 21
Axcella Therapeutics Reports Third Quarter Financial Results and Provides Update on Long COVID, OHE and NASH Clinical Trials
8:08am
8-K
EX-10.1
34m14k
7 Sep 21
Entry into a Material Definitive Agreement
4:16pm